A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
NCT01260181
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
DRUG:
Erlotinib
Sponsor
Hoffmann-La Roche